The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group
Open accessAbstract
The prognosis for patients multiple myeloma (MM) has improved substantially over the past decade with the development of new, more effective chemotherapeutic agents and regimens that possess a high level of anti-tumor activity. In spite of this important progress, however, nearly all MM patients ultimately relapse, even those who experience a complete response to initial therapy. Management of relapsed MM thus represents a vital aspect of the overall care for patients with MM and a critical area of ongoing scientific and clinical research. This comprehensive manuscript from the International Myeloma Working Group provides detailed recommendations on management of relapsed disease, with sections dedicated to diagnostic evaluation, determinants of therapy, and general approach to patients with specific disease characteristics. In addition, the manuscript provides a summary of evidence from clinical trials that have significantly impacted the field, including those evaluating conventional dose therapies, as well as both autologous and allogeneic stem cell transplantation. Specific recommendations are offered for management of first and second relapse, relapsed and refractory disease, and both autologous and allogeneic transplant. Finally, perspective is provided regarding new agents and promising directions in management of relapsed MM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Those undergoing HCT typically receive a triplet regimen for 3–4 months prior to stem cell collection in order to reduce tumor cell numbers in the bone marrow.”
From Epidemiology, Staging, and Management of Multiple Myeloma (2021) · cites this paper as [34]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Self-citationAntitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
Richardson, P. G. G., Sonneveld, P., Schuster, M. W., Irwin, D. H., Stadtmauer, E. A., Facon, T. T. F., Harousseau, J., Ben‐Yehuda, D., Lonial, S., Goldschmidt, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043445 · Cited by 2,512
Self-citationImproved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Self-citationTtal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationCarfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332
Self-citation
Cited by
Sorted by citations
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Moreau, P., Miguel, J. F. S., Sonneveld, P., Mateos, M., Zamagni, E., Avet‐Loiseau, H., Hájek, R., Dimopoulos, M. A., Ludwig, H., Einsele, H., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx096 · Cited by 901
Self-citationBrudno, J. N., Marić, I., Hartman, S. D., Rose, J. J., Wang, M., Lam, N., Stetler‐Stevenson, M., Salem, D., Yuan, C. M., Pavletic, S. Z., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.8084 · Cited by 792
Kumar, S. K., Harrison, S. J., Cavo, M., de la Rubia, J., Popat, R., Gasparetto, C., Hungria, V., Salwender, H. J., Suzuki, K., Kim, I., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30525-8 · Cited by 404
Self-citationMultiple myeloma current treatment algorithms
Rajkumar, S. V., & Kumar, S. K. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00359-2 · Cited by 373
Self-citationEpidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
“Lastly, immunomodulators like lenalidomide, pomalidomide, and thalidomide are frequently used in triplet or quadruplet induction regimens and maintenance regimens [33,34].”
BackgroundThe multiple myelomas — current concepts in cytogenetic classification and therapy
Kumar, S. K., & Rajkumar, S. V. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0018-y · Cited by 302
Self-citationMoreau, P., Kumar, S. K., Miguel, J. F. S., Davies, F. E., Zamagni, E., Bahlis, N. J., Ludwig, H., Mikhael, J. R., Terpos, E., Schjesvold, F. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30756-7 · Cited by 290
Self-citationCAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 277
Shah, N. D., Li, L., McCarty, J. M., Kaur, I., Yvon, E. S., Shaim, H., Müftüoğlu, M., Liu, E., Orlowski, R. Z., Cooper, L. J. N., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14570 · Cited by 218
Self-citationChimeric antigen receptor T-cell therapies for multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2017) · Blood · doi:10.1182/blood-2017-06-793869 · Cited by 216
Multiple myeloma in the marrow: pathogenesis and treatments
Fairfield, H. E., Falank, C. R., Avery, L. M., & Reagan, M. R. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13038 · Cited by 197
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
Nijhof, I. S., van de Donk, N. W. C. J., Zweegman, S., & Lokhorst, H. M. (2017) · Drugs · doi:10.1007/s40265-017-0841-y · Cited by 146
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Robak, P. J., & Robak, T. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0269-9 · Cited by 147
Kararoudi, M. N., Nagai, Y., Elmas, E., Pereira, M. D. S. F., Ali, S. A., Imus, P. H., Wethington, D., Borrello, I., Lee, D. A., & Ghiaur, G. (2020) · Blood · doi:10.1182/blood.2020006200 · Cited by 131
Management of multiple myeloma in the relapsed/refractory patient
Sonneveld, P. (2017) · Hematology · doi:10.1182/asheducation-2017.1.508 · Cited by 110
Gherardin, N. A., Loh, L., Admojo, L., Davenport, A. J., Richardson, K., Rogers, A. J., Darcy, P. K., Jenkins, M. R., Prince, H. M., Harrison, S. J., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22130-1 · Cited by 110
Dimopoulos, M. A., Bringhen, S., Anttila, P., Capra, M., Cavo, M., Cole, C. E., Gasparetto, C., Hungria, V., Jenner, M. W., Vorobyev, V. I., et al. (2020) · Blood · doi:10.1182/blood.2020008209 · Cited by 84
Self-citationNext-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 80
How I treat myeloma with new agents
Moreau, P. (2017) · Blood · doi:10.1182/blood-2017-05-743203 · Cited by 87
Self-citationNavigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt, H., Ashcroft, J., Szabó, Z. R., & Garderet, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3546-8 · Cited by 81
Self-citationSafety of proteasome inhibitors for treatment of multiple myeloma
Schlafer, D., Shah, K. S., Panjic, E. H., & Lonial, S. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1259310 · Cited by 71
Touzeau, C., Krishnan, A. Y., Moreau, P., Perrot, A., Usmani, S. Z., Manier, S., Cavo, M., Chamorro, C. M., Nooka, A. K., Martin, T. G., et al. (2024) · Blood · doi:10.1182/blood.2023023616 · Cited by 71
Self-citationRichardson, P. G. G., Attal, M., Campana, F., Le-Guennec, S., Hui, A., Risse, M., Corzo, K. P., & Anderson, K. C. (2017) · Future Oncology · doi:10.2217/fon-2017-0616 · Cited by 71
Self-citationOrlowski, R. Z., Moreau, P., Niesvizky, R., Ludwig, H., Oriol, A., Chng, W. J., Goldschmidt, H., Yang, Z., Kimball, A. S., & Dimopoulos, M. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.04.018 · Cited by 73
Self-citationBortezomib Treatment Modulates Autophagy in Multiple Myeloma
Lernia, G. D., Leone, P., Solimando, A. G., Buonavoglia, A., Saltarella, I., Ria, R., Ditonno, P., Silvestris, N., Crudele, L., Vacca, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020552 · Cited by 72
Laubach, J. P., Schjesvold, F. H., Mariz, M., Dimopoulos, M. A., Lech‐Marańda, E., Špıčka, I., Hungria, V., Shelekhova, T. V., Abdo, A., Jacobasch, L., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30680-x · Cited by 69
Self-citationTreatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Moreau, P., Zamagni, E., & Mateos, M. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0200-1 · Cited by 68
Self-citationHow I treat first relapse of myeloma
Harousseau, J. L., & Attal, M. (2017) · Blood · doi:10.1182/blood-2017-03-726703 · Cited by 67
A clinical perspective on plasma cell leukemia; current status and future directions
Tuazon, S. A., Holmberg, L., Nadeem, O., & Richardson, P. G. G. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00414-6 · Cited by 68
Self-citationAilawadhi, S., Kelly, K. R., Vescio, R. A., Jagannath, S., Wolf, J. L., Gharibo, M. M., Sher, T., Bojanini, L., Kirby, M. W., & Chanan-Khan, A. A. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.018 · Cited by 65
Xu, J., Wang, Q., Xu, H., Gu, C., Jiang, L., Wang, J., Wang, D., Xu, B., Mao, X., Wang, J., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0672-7 · Cited by 65
Ixazomib for the treatment of multiple myeloma
Richardson, P. G. G., Zweegman, S., O’Donnell, E., Laubach, J. P., Raje, N. S., Voorhees, P. M., Ferrari, R. H., Skácel, T., Kumar, S. K., & Lonial, S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1528229 · Cited by 61
Self-citationBotta, C., Ciliberto, D., Rossi, M., Staropoli, N., Cucè, M., Galeano, T., Tagliaferri, P., & Tassone, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016003905 · Cited by 60
Treatment of relapsed multiple myeloma: Evidence-based recommendations
Durer, C., Durer, S., Lee, S., Chakraborty, R., Malik, M. N., Rafae, A., Zar, M. A., Kamal, A., Rosko, N., Samaras, C. J., et al. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100616 · Cited by 56
Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0857-2 · Cited by 54
Self-citationTreatment of relapsed and refractory multiple myeloma
Lee, J. H., & Kim, S. (2020) · Blood Research · doi:10.5045/br.2020.s008 · Cited by 50
BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma
Yang, J., Zhou, W., Li, D., Niu, T., & Wang, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215949 · Cited by 51
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Dimopoulos, M.-A., Richardson, P., & Lonial, S. (2022) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2022.01.011 · Cited by 46
Self-citationRecent progress in relapsed multiple myeloma therapy: implications for treatment decisions
Moreau, P., & de Wit, E. (2017) · British Journal of Haematology · doi:10.1111/bjh.14780 · Cited by 46
Self-citationMultiple Myeloma Guidelines and Their Recent Updates: Implications for Imaging
Mosebach, J., Thierjung, H., Schlemmer, H.-P., & Delorme, S. (2019) · RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren · doi:10.1055/a-0897-3966 · Cited by 44
Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
Ríos, R., Agustin, M.-G., Alarcón-Payer, C., Dolores, S.-R., María, V. D. D. L. G. A., Collado, C. G., Alberto, J. M., Manuel, J. C., & Barrera, J. C. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s115456 · Cited by 43
Huynh, M., Pak, C., Markovina, S. S., Callander, N. S., Chng, K. S., Wuerzberger‐Davis, S. M., Bakshi, D. D., Kink, J. A., Hematti, P., Hope, C. L., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000667 · Cited by 40
Identification of PIKfyve kinase as a target in multiple myeloma
de Campos, C. B., Zhu, Y. X., SEPETOV, N. F., Romanov, S., Bruins, L. A., Shi, C.-X., Stein, C. K., Petit, J. L., Polito, A. N., Sharik, M. E., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222729 · Cited by 41
Yu, X. M., Fang, B., Liu, Y., Yan, S., Cao, D., Mei, H., Wang, Q., Hu, Y., & Guo, T. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117971 · Cited by 40
LeBlanc, M. R., Hirschey, R., Bryant, A. L., LeBlanc, T. W., & Smith, S. K. (2019) · Quality of Life Research · doi:10.1007/s11136-019-02392-6 · Cited by 38
Cold atmospheric plasma as a potential tool for multiple myeloma treatment
Xu, D., Xu, Y., Cui, Q., Liu, D., Liu, Z., Wang, X., Yang, Y., Feng, M., Liang, R., Chen, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24649 · Cited by 38
Laubach, J. P., Prada, C. P., Richardson, P. G. G., & Longo, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.550 · Cited by 36
Self-citationNew proteasome inhibitors in the treatment of multiple myeloma
Hungria, V. T. D. M., Crusoé, E. D. Q., Bittencourt, R., Maiolino, Â., Magalhães, R., Sobrinho, J., Pinto, J. V., Fortes, R., Moreira, E. D. S., & Tanaka, P. (2018) · Hematology, Transfusion and Cell Therapy · doi:10.1016/j.htct.2018.07.003 · Cited by 33
Shi, C.-X., Zhu, Y. X., Bruins, L. A., de Campos, C. B., Stewart, W., Braggio, E., & Stewart, A. K. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1026 · Cited by 36
Nooka, A. K., Weisel, K. C., van de Donk, N. W. C. J., Routledge, D. J. M., Rodríguez‐Otero, P., Song, K., Quach, H., Callander, N. S., Minnema, M. C., Trudel, S., et al. (2021) · Future Oncology · doi:10.2217/fon-2020-1269 · Cited by 37
Self-citationGengenbach, L., Graziani, G., Reinhardt, H., Rösner, A., Braun, M., Möller, M., Greil, C., Wäsch, R., & Engelhardt, M. M. (2021) · Cancers · doi:10.3390/cancers13174320 · Cited by 37
Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab
Shen, F., & Shen, W. (2022) · Technology in Cancer Research & Treatment · doi:10.1177/15330338221106563 · Cited by 35
Avivi, I. M., Cohen, Y. C., Suska, A., Shragai, T., Mikala, G., Garderet, L., Gueye, M. S., Glickman, S., Jayabalan, D. S., Niesvizky, R., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25579 · Cited by 34
Self-citationChen, D., Chen, B., & Yao, F. (2018) · Nanoscale Research Letters · doi:10.1186/s11671-018-2782-0 · Cited by 32
A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma
Cook, G., Zweegman, S., Mateos, M., Suzan, F., & Moreau, P. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.11.016 · Cited by 32
Self-citationCurrent approaches to management of high‐risk multiple myeloma
Goldman‐Mazur, S., & Kumar, S. K. (2021) · American Journal of Hematology · doi:10.1002/ajh.26161 · Cited by 32
Self-citationBringhen, S., Pour, L., Vorobyev, V. I., Vural, F., Warzocha, K., Benboubker, L., Koh, Y., Maisnar, V., Karlin, L., Pavic, M., et al. (2021) · Leukemia Research · doi:10.1016/j.leukres.2021.106576 · Cited by 31
Self-citationLisenko, K., Pavel, P., Kriegsmann, M., Bruckner, T. M., Hillengaß, J., Goldschmidt, H., Witzens‐Harig, M., Ho, A. D., & Wuchter, P. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.631 · Cited by 31
Leoh, L. S., Kim, Y. K., Candelaria, P. V., Martı́nez-Maza, O., Daniels‐Wells, T. R., & Penichet, M. L. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1700787 · Cited by 31
Outcomes after biochemical or clinical progression in patients with multiple myeloma
Goldman‐Mazur, S., Visram, A., Kapoor, P., Dispenzieri, A. A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kourelis, T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007082 · Cited by 30
Self-citationDrug targets and resistance mechanisms in multiple myeloma
Naß, J., & Efferth, T. (2018) · Cancer Drug Resistance · doi:10.20517/cdr.2018.04 · Cited by 28
Ahmedzai, S. H., Snowden, J. A., Ashcroft, A. J., Cairns, D. A., Williams, C. D., Hockaday, A., Cavenagh, J. D., Ademokun, D., Tholouli, E., Allotey, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01006 · Cited by 27
Huang, F.-I., Wu, Y.-W., Sung, T.-Y., Liou, J., Lin, M., Pan, S., & Yang, C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00249 · Cited by 26
Möller, M., Ihorst, G., Pahl, A., Scheubeck, S., Barsch, F., Dold, S. M., Bertz, H., Arends, J., Wäsch, R., & Engelhardt, M. M. (2020) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2020.11.003 · Cited by 28
Liu, Q., Ran, R., Song, M., Li, X., Wu, Z., Guanrong, D., & Xia, R. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-021-09628-7 · Cited by 27
Xia, J., Sun, Q., Zhou, D., Li, H., Wang, Y., Qi, Y., Cao, J., Yan, Z., Li, D., Cheng, H., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00048-1 · Cited by 27
Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
Sparano, F., Cavo, M., Niscola, P., Caravita, T., & Efficace, F. (2018) · Supportive Care in Cancer · doi:10.1007/s00520-018-4137-x · Cited by 26
Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma
Shi, J., Song, S., Han, H., Xu, H., Huang, M., Qian, C., Zhang, X., Ouyang, L., Hong, Y., Zhuang, W., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00554 · Cited by 26
Brigle, K. E., Pierre, A. E., Finley-Oliver, E., Faiman, B. M., Tariman, J. D., Miceli, T. S., & and Board (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.s5.60-76 · Cited by 26
Brianna, B., Ling, A. P. K., & Wong, Y. P. (2022) · Stem Cell Investigation · doi:10.21037/sci-2022-021 · Cited by 25
Outcome of a Salvage Third Autologous Stem Cell Transplantation in Multiple Myeloma
Garderet, L., Iacobelli, S., Köster, L., Goldschmidt, H., Johansson, J., Bourhis, J. H., Krejčí, M., Leleu, X. P., Potter, M. N., Blaise, D., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.035 · Cited by 25
Self-citationProgression with clinical features is associated with worse subsequent survival in multiple myeloma
Chakraborty, R., Liu, H. D., Rybicki, L. A., Tomer, J., Khouri, J., Dean, R. M., Faiman, B. M., Kalaycio, M. E., Samaras, C. J., Majhail, N. S., et al. (2019) · American Journal of Hematology · doi:10.1002/ajh.25415 · Cited by 24
Moreau, P., Dimopoulos, M. A., Richardson, P. G. G., Siegel, D. S. D., Cavo, M., Corradini, P., Weisel, K. C., Delforge, M., O’Gorman, P., Song, K., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12903 · Cited by 24
Self-citationTan, D. C. L., Lee, J. H., Chen, W.-M., Shimizu, K., Hou, J., Suzuki, K., Nawarawong, W., Huang, S., Chim, C. S., Kım, K., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1427858 · Cited by 25
Self-citationTherapeutic progress in relapsed/refractory multiple myeloma
Chen, Q., Zhang, M., Zheng, S., Tong, Y., & Tan, Y. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05730-y · Cited by 26
Primary Plasma Cell Leukemia: Identity Card 2016
Musto, P., Simeon, V., Todoerti, K., & Neri, A. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0392-6 · Cited by 22
Nieto, Y. L., Valdez, B. C., Pingali, S. R., Bassett, R. L., Delgado, R., Nguyen, J., Shah, N. D., Popat, U., Jones, R. B., Andersson, B. S., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30080-7 · Cited by 22
Self-citationKastritis, E., Ρούσσου, Μ., Gavriatopoulou, M., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., Ziogas, D. C., Fotiou, D., Ntanasis‐Stathopoulos, I., Dialoupi, I., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000539 · Cited by 22
Self-citationUsmani, S. Z., Karanes, C., Bensinger, W., D’Souza, A., Raje, N. S., Tuchman, S. A., Sborov, D. W., Laubach, J. P., Bianchi, G., Kanagavel, D., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01262-w · Cited by 22
Self-citationSafety of ixazomib for the treatment of multiple myeloma
Bonnet, A., & Moreau, P. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1344212 · Cited by 23
Self-citationPatriarca, F. F., Bruno, B., Einsele, H., Spina, F., Giaccone, L., Montefusco, V., Isola, M., Nozzoli, C., Nozza, A., Morabito, F., et al. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.10.014 · Cited by 21
Self-citationNew developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
Richardson, P. G. G., Kumar, S. K., Laubach, J. P., Paba‐Prada, C. E., Gupta, N., Berg, D. T., de Velde, H. J. V., & Moreau, P. (2017) · Journal of Blood Medicine · doi:10.2147/jbm.s102328 · Cited by 20
Self-citationRichardson, P. G. G., Harrison, S. J., Bringhen, S., Schjesvold, F. H., Yong, K., Campana, F., Le-Guennec, S., Macé, S., & Dimopoulos, M. A. (2021) · Future Oncology · doi:10.2217/fon-2021-0568 · Cited by 20
Self-citationHaertle, L., Barrio, S., Munawar, U., Han, S., Zhou, X., Šimíček, M., Vogt, C., Truger, M. S., Alonso, R., Steinhardt, M., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1161 · Cited by 20
Self-citationKatodritou, E., Kyrtsonis, M., Delimpasi, S., Kyriakou, D. S., Symeonidis, A. S., Spanoudakis, E., Vasilopoulos, G., Anagnostopoulos, Α., Kioumi, A., Zikos, P., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3361-2 · Cited by 20
Self-citationWang, B., Lyu, H., Pei, S., Song, D., Ni, J., & Liu, B. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1464849 · Cited by 18
Dimopoulos, M. A., Niesvizky, R., Weisel, K. C., Siegel, D. S. D., Hájek, R., Mateos, M., Cavo, M., Huang, M., Zahlten‐Kumeli, A., & Moreau, P. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0300-y · Cited by 19
Self-citationChromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse
Smetana, J., Oppelt, J., Štork, M., Pour, L., & Kuglík, P. (2018) · Molecular Cytogenetics · doi:10.1186/s13039-018-0357-5 · Cited by 18
Added prognostic value of FDG-PET/CT in relapsing multiple myeloma patients
Jamet, B., Bailly, C., Carlier, T., Planche, L., Touzeau, C., Kraeber‐Bodéré, F., Moreau, P., & Bodet‐Milin, C. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1459602 · Cited by 16
Self-citationNielsen, L. K., Abildgaard, N., Jarden, M., & Klausen, T. (2019) · British Journal of Haematology · doi:10.1111/bjh.15759 · Cited by 18
Bila, J., Katodritou, E., Guenova, M. L., Bašić‐Kinda, S., Coriu, D., Dapcevic, M., Ibricevic-Balić, L., Ivanaj, A., Каранфилски, О., Zver, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173940 · Cited by 17
Self-citationWang, J., Gu, T., Hu, Y., & Huang, H. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00316-8 · Cited by 16
Mark, T. M., Forsberg, P. A., Rossi, A., Pearse, R. N., Pekle, K. A., Perry, A., Boyer, A. S., Tegnestam, L., Jayabalan, D. S., Coleman, M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028027 · Cited by 16
Khouri, J., Faiman, B. M., Grabowski, D., Mahfouz, R. Z., Khan, S. N., Wei, W., Valent, J. N., Dean, R. M., Samaras, C. J., Jha, B. K., et al. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.004 · Cited by 16
Effects of time delays in a mathematical bone model
Wang, L., Qiu, K., & Jia, Y. (2017) · Chinese Physics B · doi:10.1088/1674-1056/26/3/030503 · Cited by 16
Kinahan, C., Mangone, M. A., Scotto, L., Visentin, M., Marchi, E., Cho, H. J., & O’Connor, O. A. (2020) · Oncotarget · doi:10.18632/oncotarget.27516 · Cited by 15
Kansai Myeloma Forum Investigators, Matsumura‐Kimoto, Y., Kuroda, J., Kaneko, H., Kamitsuji, Y., Fuchida, S., Nakaya, A., Shibayama, H., Uoshima, N., Yokota, I., et al. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2416-4 · Cited by 15
Nawrocki, S. T., Olea, J., Celi, C. V., Dadrastoussi, H., Wu, K., Tsao-Wei, D. D., Colombo, A., Coffey, M. C., Hernandez, E. F., Chen, X., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0229 · Cited by 17
Parisi, M. S., Leotta, S., Romano, A., Fabro, V. D., Martino, E. A., Calafiore, V., Giubbolini, R., Markovic, U., Leotta, V., Giorgio, M. A. D., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101695 · Cited by 14
The BET Bromodomain Inhibitor OTX015 Synergizes with Targeted Agents in Multiple Myeloma
Gu, J., Song, S., Han, H., Xu, H., Gao, F., Qian, C., Qiu, Y., Zhou, W., Zhuang, W., & Li, B.-Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00880 · Cited by 14
Metadata
- Authors
- Laubach, J., Garderet, L., Mahindra, A., Gahrton, G., Caers, J., Sezer, O., Voorhees, P., Leleu, X., Johnsen, H. E., Streetly, M., Jurczyszyn, A., Ludwig, H., Mellqvist, U.-H., Chng, W.-J., Pilarski, L., Einsele, H., Hou, J., Turesson, I., Zamagni, E., Chim, C. S., Mazumder, A., Westin, J., Lu, J., Reiman, T., Kristinsson, S., Joshua, D., Roussel, M., O'Gorman, P., Terpos, E., McCarthy, P., Dimopoulos, M., Moreau, P., Orlowski, R. Z., Miguel, J. S., Anderson, K. C., Palumbo, A., Kumar, S., Rajkumar, V, Durie, B., & Richardson, P. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Hôpital Saint-Antoine (FR)
- University of California, San Francisco (US)
- Karolinska University Hospital (SE)
- Centre Hospitalier Universitaire de Liège (BE)
- Istanbul Memorial Hospital (TR)
- University of North Carolina at Chapel Hill (US)
- Centre Hospitalier Universitaire de Lille (FR)
- Aalborg University Hospital (DK)
- King's College Hospital (GB)
- Jagiellonian University (PL)
- Wilhelminen Hospital (AT)
- Sahlgrenska University Hospital (SE)
- National University of Singapore (SG)
- University of Alberta (CA)
- Universitätsklinikum Würzburg (DE)
- Second Military Medical University (CN)
- Skåne University Hospital (SE)
- University of Bologna (IT)
- Queen Mary Hospital (CN)
- NYU Langone Health (US)
- Peking University People's Hospital (CN)
- Dalhousie University (CA)
- Royal Prince Alfred Hospital (AU)
- Hôpital Purpan (FR)
- National and Kapodistrian University of Athens (GR)
- Roswell Park Comprehensive Cancer Center (US)
- Nantes Université (FR)
- The University of Texas MD Anderson Cancer Center (US)
- University of Turin (IT)
- Mayo Clinic (US)
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Richardson, P G
- ORCID
- Laubach, J
- Garderet, L
- Caers, J
- Sezer, O
- Voorhees, P
- Leleu, X
- Johnsen, H E
- Streetly, M
- Jurczyszyn, A
- Ludwig, H
- Einsele, H
- Hou, J
- Turesson, I
- Zamagni, E
- Chim, C S
- Mazumder, A
- Reiman, T
- Kristinsson, S
- Roussel, M
- Terpos, E
- McCarthy, P
- Dimopoulos, M
- Moreau, P
- Orlowski, R Z
- Anderson, K C
- Palumbo, A
- Kumar, S
- Durie, B
- Richardson, P G
- Venue
- Leukemia
- Published
- 2015-12-29
- Volume
- 30
- Issue
- 5
- Pages
- 1005-1017
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2216303864
- Cited by
- 258
- References
- 133
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 10 · 2023: 33 · 2022: 24 · 2021: 25 · 2020: 35 · 2019: 29 · 2018: 32 · 2017: 38 · 2016: 10
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- ORBi (University of Liège) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- relapsed multiple myeloma, relapsed/refractory multiple myeloma, second relapse, autologous stem cell transplantation, allogeneic stem cell transplantation, conventional-dose chemotherapy, diagnostic assessment, treatment selection
- MeSH terms
- Antineoplastic Agents, Humans, Multiple Myeloma, Recurrence, Salvage Therapy, Practice Guidelines as Topic, Hematopoietic Stem Cell Transplantation, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
